The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study Rationale and Design
Open Access
- 30 June 2020
- journal article
- research article
- Published by American Thoracic Society in Annals of the American Thoracic Society
- Vol. 17 (7), 879-891
- https://doi.org/10.1513/AnnalsATS.202003-192SD
Abstract
There is broad interest in improved methods to generate robust evidence regarding best practice, especially in settings where patient conditions are heterogenous and require multiple concomitant therapies. Here, we present the rationale and design of a large, international trial that combines features of adaptive platform trials with pragmatic point-of-care trials to determine best treatment strategies for patients admitted to an intensive care unit with severe community-acquired pneumonia. The trial uses a novel design, entitled "a randomized embedded multifactorial adaptive platform." The design has five key features: 1) randomization, allowing robust causal inference; 2) embedding of study procedures into routine care processes, facilitating enrollment, trial efficiency, and generalizability; 3) a multifactorial statistical model comparing multiple interventions across multiple patient subgroups; 4) response-adaptive randomization with preferential assignment to those interventions that appear most favorable; and 5) a platform structured to permit continuous, potentially perpetual enrollment beyond the evaluation of the initial treatments. The trial randomizes patients to multiple interventions within four treatment domains: antibiotics, antiviral therapy for influenza, host immunomodulation with extended macrolide therapy, and alternative corticosteroid regimens, representing 240 treatment regimens. The trial generates estimates of superiority, inferiority, and equivalence between regimens on the primary outcome of 90-day mortality, stratified by presence or absence of concomitant shock and proven or suspected influenza infection. The trial will also compare ventilatory and oxygenation strategies, and has capacity to address additional questions rapidly during pandemic respiratory infections. As of January 2020, REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) was approved and enrolling patients in 52 intensive care units in 13 countries on 3 continents. In February, it transitioned into pandemic mode with several design adaptations for coronavirus disease 2019. Lessons learned from the design and conduct of this trial should aid in dissemination of similar platform initiatives in other disease areas.Keywords
This publication has 79 references indexed in Scilit:
- Hydroxyethyl Starch or Saline for Fluid Resuscitation in Intensive CareNew England Journal of Medicine, 2012
- A point-of-care clinical trial comparing insulin administered using a sliding scale versus a weight-based regimenClinical Trials, 2011
- Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory MedicationsClinical Microbiology Reviews, 2010
- Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unitClinical Therapeutics, 2010
- Critical Care Services and 2009 H1N1 Influenza in Australia and New ZealandNew England Journal of Medicine, 2009
- Antibiotics for community acquired pneumonia in adult outpatientsPublished by Wiley ,2009
- Severe community-acquired pneumoniaCurrent Opinion in Critical Care, 2004
- Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2000
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Statistics and ethics in medical research: III How large a sample?BMJ, 1980